表皮生长因子受体抑制剂在转移性肛门管癌治疗中的作用：病例系列研究。
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.
机构信息
Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY 10032-3784, USA.
出版信息
J Oncol. 2011;2011:125467. doi: 10.1155/2011/125467. Epub 2011 Jun 13.
Abstract
Anal cancer patients who have exhibited disease progression after having received all approved drugs pose a major therapeutic challenge. In addition to cytotoxic agents, novel targeted agents are being developed and have an established role in the treatment of many solid tumors, including colon cancer. However, their role in anal cancer is yet to be determined. Most anal malignancies are squamous cell carcinomas often strongly expressing epidermal growth factor receptors (EGFRs). Targeting the latter seems to result in favorable changes in tumor growth. We present three cases of refractory anal cancers, treated with EGFR inhibitors, after having received the recommended chemotherapy regimens. We conclude that EGFR inhibitors may play a vital role in the treatment of anal cancer and we suggest that large trials are be conducted in order to clarify their efficacy and to improve therapeutic management.
摘要
接受所有已批准药物后仍出现疾病进展的肛门癌患者带来了重大的治疗挑战。除细胞毒性药物外，新型靶向药物也在不断开发，并在包括结肠癌在内的许多实体瘤的治疗中发挥着重要作用。然而，它们在肛门癌中的作用尚待确定。大多数肛门恶性肿瘤为鳞状细胞癌，通常强烈表达表皮生长因子受体 (EGFRs)。针对后者似乎会导致肿瘤生长发生有利的变化。我们报告了三例接受推荐化疗方案后使用 EGFR 抑制剂治疗的难治性肛门癌病例。我们的结论是，EGFR 抑制剂可能在肛门癌的治疗中发挥重要作用，我们建议进行大规模试验以明确其疗效并改善治疗管理。
相似文献
1
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.表皮生长因子受体抑制剂在转移性肛门管癌治疗中的作用：病例系列研究。
J Oncol. 2011;2011:125467. doi: 10.1155/2011/125467. Epub 2011 Jun 13.
2
Epidermal growth factor receptor inhibition in metastatic anal cancer.转移性肛管癌中表皮生长因子受体抑制作用
Anticancer Drugs. 2016 Sep;27(8):804-8. doi: 10.1097/CAD.0000000000000383.
3
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.表皮生长因子受体和 K-RAS 状态在两个鳞状细胞癌队列中。
BMC Cancer. 2010 May 11;10:189. doi: 10.1186/1471-2407-10-189.
4
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.表皮生长因子受体抑制剂治疗晚期肛管鳞状细胞癌患者：单机构经验
Oncology. 2017;92(4):190-196. doi: 10.1159/000452766. Epub 2017 Feb 3.
5
[Metastatic squamous cell carcinomas of the anal canal: Current management and prospects].[肛管转移性鳞状细胞癌：当前治疗与展望]
Bull Cancer. 2020 Jul-Aug;107(7-8):792-799. doi: 10.1016/j.bulcan.2020.04.016. Epub 2020 Jun 24.
6
Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.肛管转移性鳞状细胞癌患者中与人乳头瘤病毒/p16相关的临床病理特征
Oncologist. 2015 Nov;20(11):1247-52. doi: 10.1634/theoncologist.2015-0091. Epub 2015 Sep 17.
7
Epidermal growth factor receptor expression in anal canal carcinoma.肛管癌中表皮生长因子受体的表达
Am J Clin Pathol. 2005 Jul;124(1):20-3. doi: 10.1309/X4UADHVN317V2XMW.
8
Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.西妥昔单抗联合顺铂和5-氟尿嘧啶可使转移性难治性肛管鳞状细胞癌产生显著疗效。
J Gastrointest Oncol. 2015 Oct;6(5):E82-5. doi: 10.3978/j.issn.2078-6891.2015.035.
9
Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab.一名患有逆转录病毒感染的患者，其复发性难治性转移性肛管鳞状细胞癌对西妥昔单抗有反应。
J Oncol Pharm Pract. 2020 Jun;26(4):1025-1028. doi: 10.1177/1078155219884605. Epub 2019 Nov 4.
10
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.多西他赛、顺铂和氟尿嘧啶化疗治疗转移性或不可切除的局部复发性肛门鳞状细胞癌（Epitopes-HPV02）：一项多中心、单臂、Ⅱ期研究。
Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.
引用本文的文献
1
Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer.希腊医学肿瘤学会（HESMO）肛门癌管理指南。
Updates Surg. 2021 Feb;73(1):7-21. doi: 10.1007/s13304-020-00923-2. Epub 2020 Nov 24.
2
Systemic Therapies for Advanced Squamous Cell Anal Cancer.晚期鳞状细胞肛门癌的系统治疗。
Curr Oncol Rep. 2018 May 4;20(7):53. doi: 10.1007/s11912-018-0698-6.
3
Overview of Recent Trends in the Management of Metastatic Anal Cancer.转移性肛管癌治疗的近期趋势概述
World J Oncol. 2015 Feb;6(1):311-315. doi: 10.14740/wjon866w. Epub 2015 Feb 14.
4
Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.199例肛管鳞状细胞癌的综合多平台生物标志物分析
Oncotarget. 2015 Dec 22;6(41):43594-604. doi: 10.18632/oncotarget.6202.
5
Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.西妥昔单抗联合顺铂和5-氟尿嘧啶可使转移性难治性肛管鳞状细胞癌产生显著疗效。
J Gastrointest Oncol. 2015 Oct;6(5):E82-5. doi: 10.3978/j.issn.2078-6891.2015.035.
6
Cetuximab in refractory squamous cell carcinoma of the anal canal.西妥昔单抗治疗难治性肛管鳞状细胞癌。
J Gastrointest Cancer. 2014 Dec;45 Suppl 1:198-200. doi: 10.1007/s12029-014-9626-7.
7
EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?表皮生长因子受体和 K-ras 基因突变状态在鳞状细胞肛门癌中的作用：同期放化疗和表皮生长因子抑制剂的作用？
Br J Cancer. 2012 Nov 20;107(11):1864-8. doi: 10.1038/bjc.2012.479. Epub 2012 Oct 23.
8
Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm?肛门转移性鳞状细胞癌：是时候转变治疗模式了吗？
ISRN Oncol. 2012;2012:756591. doi: 10.5402/2012/756591. Epub 2012 May 6.
本文引用的文献
1
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.分析 KRAS、BRAF、PTEN、IGF1R、EGFR 内含子 1 CA 状态在原发性肿瘤和配对转移瘤中的情况，以确定西妥昔单抗治疗结肠癌的获益。
Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.
2
Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.帕尼单抗治疗西妥昔单抗进展后的安全性和疗效：两家机构的经验。
Clin Colorectal Cancer. 2010 Dec;9(5):315-8. doi: 10.3816/CCC.2010.n.046.
3
Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications.表皮生长因子受体（EGFR）信号网络的核模式：生物学、预后价值及治疗意义
Discov Med. 2010 Jul;10(50):44-51.
4
The role of the pathologist in rectal cancer diagnosis and staging and surgical quality assessment.病理学家在直肠癌诊断、分期和手术质量评估中的作用。
Clin Transl Oncol. 2010 May;12(5):339-45. doi: 10.1007/s12094-010-0515-7.
5
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.表皮生长因子受体和 K-RAS 状态在两个鳞状细胞癌队列中。
BMC Cancer. 2010 May 11;10:189. doi: 10.1186/1471-2407-10-189.
6
Epidermal growth factor receptor inhibitors: current status and future directions.表皮生长因子受体抑制剂：现状与未来方向
Curr Probl Cancer. 2009 Jul-Aug;33(4):245-94. doi: 10.1016/j.currproblcancer.2009.10.002.
7
Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.西妥昔单抗为基础的转移性肛门癌的治疗：反应与 KRAS 基因突变状态的相关性。
Oncology. 2009;77(5):293-9. doi: 10.1159/000259615. Epub 2009 Nov 17.
8
Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus.肛门鳞状病变中生长因子受体的表达：与致癌性人乳头瘤病毒和人类免疫缺陷病毒相关的改变
Hum Pathol. 2009 Nov;40(11):1517-27. doi: 10.1016/j.humpath.2009.05.010. Epub 2009 Aug 27.
9
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.联合腹腔化疗在体内对结直肠癌肝转移的疗效优于丝裂霉素 C 或奥沙利铂。
Ann Surg Oncol. 2010 Jan;17(1):296-303. doi: 10.1245/s10434-009-0669-0. Epub 2009 Aug 26.
10
Integration of panitumumab into the treatment of colorectal cancer.帕尼单抗在结直肠癌治疗中的应用。
Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Epub 2009 Jul 17.
Zotero 插件